Raludotatug deruxtecan

DB19447InvestigationalProtein Based Therapies

Raludotatug deruxtecan is under investigation in clinical trial NCT06660654 (A Study of Raludotatug Deruxtecan in Participants With Advanced/metastatic Solid Tumors (Rejoice-pantumor01)).

Mechanism: Pharmacologically active on Cadherin-6
Curator reviewed
Also known as: gamma1 heavy chain humanized (1-452) [VH (Homo sapiens IGHV1-3*01 (86.7%)-(IGHD)-IGHJ4*01(93.3%), CDR-IMGT [8.8.15] (26-33.51-58.97-111))(1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (219)(123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 E12 (3 · immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative · R-DXd
Code names: DS-6000a · MK-5909

Resolves to

Compound

UNIIBPQ010OFD7CAS2610074-57-0

Targets

P55285CDH6

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Raludotatug deruxtecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account